View ValuationSSY Group 향후 성장Future 기준 점검 4/6SSY Group (는) 각각 연간 21.2% 및 13% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 21.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 11.2% 로 예상됩니다.핵심 정보21.2%이익 성장률21.61%EPS 성장률Pharmaceuticals 이익 성장15.0%매출 성장률13.0%향후 자기자본이익률11.18%애널리스트 커버리지Low마지막 업데이트17 Jul 2026최근 향후 성장 업데이트공고 • Feb 16SSY Group Limited Provides Group Earnings Guidance for the Year Ended 31 December 2025SSY Group Limited provided group earnings guidance for the year ended 31 December 2025. The board of directors of the Company (the "Board") informed shareholders of the Company (the "Shareholders") and potential investors that, based on the information currently available to the Board and after preliminary assessment of the Group's unaudited management accounts for the year ended 31 December 2025, the Board preliminarily estimates that the Group is expected to record a reduction in profit attributable to equity shareholders of the Company for the year ended 31 December 2025 in the range of 45% to 60% as compared to profit attributable to equity shareholders of the Company of HKD 1,061,150,000 for the year ended 31 December 2024. The estimated reduction in the profit attributable to equity shareholders of the Company is mainly attributable to the decline in turnover due to the following factors: the influenza outbreak in the PRC led to strong market demand for intravenous infusion solutions and other medicines in the first quarter of 2024, but the terminal sales volume of medicines has declined due to the absence of large-scale epidemic in the PRC and the control of medical insurance cost throughout the year ended 31 December 2025; the expansion of various forms of volume-based procurement (including the National Centralised Medicines Procurement and local alliance centralised procurement) and the intensification of domestic and international industry competition have brought about continuing price pressure; and turnover of Bromhexine Hydrochloride in ampoule injection decreased as it was no longer sold through National Centralized Medicines Procurement.모든 업데이트 보기Recent updates공고 • Jul 23SSY Group Limited Announces Update on Drug Approvals Enhancing Diversified Pharmaceutical Product PortfolioThe board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for the following four products from National Medical Products Administration of China, all being under type 4 chemical drug and regarded as passing the consistency evaluation. Hemofiltration Replacement Fluid of Sodium Citrate (5000ml): This product is mainly used as a replacement fluid in continuous renal replacement therapy (CRRT) with local citrate anticoagulation, and is particularly suitable for patients such as those with an increased risk of bleeding who are not advised for systemic anticoagulation with heparin. Compared to clinical mainstream split citrate formula (bicarbonate replacement fluid combined with a separate sodium citrate anticoagulant), this product has significant clinical advantages and a promising market prospect. The Group is actively developing large-volume injections such as hemofiltration replacement solutions and peritoneal dialysis solutions, further improving its product portfolio. Benidipine Hydrochloride Tablets (4mg): This product is mainly used for the treatment of primary hypertension and angina pectoris. The Group has established a comprehensive hypertension product portfolio, covering 2nd and 3rd generation calcium channel blockers, ACE inhibitors, -receptor blockers, and multiple single- tablet compound preparations, along with intravenous emergency antihypertensive drugs used in intensive care unit (ICU). Among which, the Group's Benidipine Hydrochloride Tablets in 8mg specification has been approved for market and selected in the tender result of the eleventh batch of the National Centralised Medicines Procurement. With the approval of its 4mg specification, the initial low-dose treatment needs for hypertension can be fully met, forming a complete dose gradient of "initial titration 4mg + maintenance therapy 8mg". Polyvinyl Alcohol Eye Drops 1.4% (0.4ml: 5.6mg): This product is mainly used as a lubricant for prevention or treatment of irritation symptoms such as dry eyes, foreign matter sensation and eye fatigue, or for improvement of eye dryness symptoms. Polyvinyl Alcohol Eye Drop is in single-dose packaging, preservative-free, and is an OTC product for office workers experiencing eye strain, people spending long time at screens or with sensitive ocular surfaces for their immediate relief of dry eyes. The Group has a strategic layout in ophthalmic drug segment with single-dose and preservative-free formulations, and has built a product portfolio including anti-infectives, anti-allergens, intraocular pressure lowering, artificial tears and ocular anti-inflammatory, forming a dual-channel layout of in-hospital prescription drugs and retail OTC. Fat Emulsion, Amino Acids (17) and Glucose (19%) Injection (1540ml and 1026ml): This product is mainly used for adult patients who are unable, with impaired function or not advised for receiving nutrition orally or enterally. This product is a complex three-chamber bag preparation for parenteral nutrition with high technological barriers. It is mainly used for intravenous nutritional support in adult patients after surgery, those with tumors or in ICU. The newly approved 1540ml and 1026ml specifications can meet the individualised clinical needs of patients with different weights and energy requirements. The Group is systematically developing a parenteral nutrition product platform covering premixed three-chamber bag all-in-one preparations, nutrients, vitamins, trace elements and electrolyte supplements. This approval further enhances the Group's high-end intravenous nutrition product portfolio, creating synergy with its basic infusion, amino acid and fat emulsion series, and will bring a positive effect on its expansion into the perioperative and critical care nutrition markets.공고 • Jul 21SSY Group Limited Obtains Approval For Registration Of Gadobutrol As Bulk Drug For Market PreparationsSSY Group Limited has announced that the Group’s Gadobutrol has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Gadobutrol is a magnetic resonance imaging contrast agent used for adults and children of all ages (including full-term newborns), and is mainly used for contrast-enhanced magnetic resonance imaging (CE-MRI) examinations of lesions in various parts of the body (including the brain and spinal cord), as well as contrast-enhanced magnetic resonance angiography (CE-MRA) examinations of various parts of the body. Gadobutrol, as a new generation of magnetic resonance imaging contrast agent with macrocyclic structure, is more stable and safer than Gadopentetate Dimeglumine with linear structure, offering advantage for clinical substitution. Gadolinium is a rare-earth metal, and the Group is actively developing an integrated business of bulk drugs and injection preparations under Gadolinium category.공고 • Jul 18Ssy Group Limited Obtains Approval for Drug Production and Registration of Choline Fenofibrate Sustained-Release CapsulesSSY Group Limited has obtained the approval for drug production and registration for Choline Fenofibrate Sustained-release Capsules (135mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Choline Fenofibrate Sustained-release Capsule is mainly used in adults with controlled diets for lowering triglyceride levels in patients with severe hypertriglyceridemia, and for treatment of patients with primary hypercholesterolemia or mixed dyslipidemia. As compared to traditional fenofibrate, choline fenofibrate has a direct effect, a lower liver and kidney burden, can be taken without dietary restrictions and safely combined with statins drug, making it a high-end triglyceride-lowering product of next generation with clinical necessity.공고 • Jul 13SSY Group Limited Obtains Approval for Registration of Baloxavir Marboxil as Bulk Drug in ChinaSSY Group Limited announced that the Group’s Baloxavir Marboxil has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Baloxavir Marboxil is mainly used for the treatment of influenza A and influenza B.공고 • Jul 10+ 1 more updateSSY Group Limited Announces Inclusion of 95 Types of Products in National Essential Medicines List (2026 Edition)SSY Group Limited announced that a total of 95 types (with 141 specifications) of products of the Group have been included in the National Essential Medicines List (2026 Edition) of China, including the newly added 32 types (with 37 specifications), namely Glucose & Sodium Chloride Injection, Levofloxacin Lactate & Sodium Chloride Injection, Levofloxacin & Sodium Chloride Injection, Sodium Bicarbonate Injection, Fluconazole Tablets, Gliclazide Tablets, Clear Heat & Detox Oral Liquid, Potassium Chloride Injection, Mecobalamin Injection, Ambroxol Hydrochloride Injection, Bromhexine Hydrochloride Injection, Medium/Long Chain Fat Emulsion Injection, Azithromycin for Injection, Paracetamol Tablets, Azithromycin for Suspension, Ipratropium Bromide Solution for Inhalation, Lurasidone Hydrochloride Tablets, Urapidil Hydrochloride Injection, Citicoline Sodium Injection, Oseltamivir Phosphate for Suspension, Aminophylline Injection, Magnesium Sulfate Injection, Cefuroxime Axetil for Suspension, Ondansetron Hydrochloride Injection, Entacapone Tablets, Isosorbide Dinitrate Injection, Betahistine Mesilate Tablets, Norepinephrine Bitartrate Injection, Levamlodipine Besilate Tablets, Levofloxacin Eye Drops, Propafenone Hydrochloride Injection and Metoclopramide Hydrochloride Injection. The List will become effective on 1 September 2026, which is expected to have a positive impact on the growth and business development of the Group. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Jun 24SSY Group Limited Obtains Approval for Drug Production and Registration for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation SolutionSSY Group Limited has obtained the approval for drug production and registration for Safinamide Mesylate Tablets (100mg and 50mg) from National Medical Products Administration of China (the NMPA), being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Safinamide Mesylate Tablet is mainly used in combination therapy for adult patients with primary Parkinson’s disease and symptoms fluctuation, in combination with other drugs for Parkinson’s disease such as levodopa. As stated in the Company’s announcement dated 26 May 2026, the Group’s Safinamide Mesylate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Group has obtained the approval for drug production and registration for Procaterol Hydrochloride Inhalation Solution (0.3ml: 30µg) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Procaterol Hydrochloride Inhalation Solution is mainly used in the relief of various symptoms based on airflow limitation in bronchial asthma, chronic bronchitis and emphysema.공고 • Jun 09Ssy Group Limited Obtains Approval to Become Market Authorization Holder of Ceftizoxime Sodium for InjectionSSY Group Limited has obtained the approval from the National Medical Products Administration of China for the change to become the market authorization holder of Ceftizoxime Sodium for Injection (1g and 0.5g). Ceftizoxime Sodium for Injection is mainly used for the treatment of (1) lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections caused by susceptible bacteria; (2) meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae; and (3) uncomplicated gonorrhea. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Guangce Jiang was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 22Ssy Group Limited Announces Furosemide Obtains Approval for Registration in ChinaThe board of directors of SSY Group Limited is announcing that the Group’s Furosemide has obtained the approval for registration from the National Medical Products Administration of China to become bulk drug for the preparations on the market. As stated in the Company’s announcements dated 30 June 2025 and 27 December 2024 respectively, the Group has obtained the approvals for drug production and registration for Furosemide Tablet and Furosemide Injection from the NMPA. Furosemide is mainly used for the treatment of various diseases with edema, hypertension, hyperkalemia and hypercalcemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and acute drug poisoning (such as barbiturate poisoning), and for the prevention of acute kidney failure. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Mar 27SSY Group Limited, Annual General Meeting, May 15, 2026SSY Group Limited, Annual General Meeting, May 15, 2026, at 14:00 China Standard Time. Location: rooms 4902-03, 49th floor, central plaza, 18 harbour road, wanchai., Hong Kong공고 • Mar 17SSY Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026SSY Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026공고 • Mar 06Ssy Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Calcium Levofolinate for Injection (25mg) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Calcium Levofolinate for Injection is mainly used for the treatment of gastric cancer and colorectal cancer in combination with 5-fluorouracil.공고 • Feb 16SSY Group Limited Provides Group Earnings Guidance for the Year Ended 31 December 2025SSY Group Limited provided group earnings guidance for the year ended 31 December 2025. The board of directors of the Company (the "Board") informed shareholders of the Company (the "Shareholders") and potential investors that, based on the information currently available to the Board and after preliminary assessment of the Group's unaudited management accounts for the year ended 31 December 2025, the Board preliminarily estimates that the Group is expected to record a reduction in profit attributable to equity shareholders of the Company for the year ended 31 December 2025 in the range of 45% to 60% as compared to profit attributable to equity shareholders of the Company of HKD 1,061,150,000 for the year ended 31 December 2024. The estimated reduction in the profit attributable to equity shareholders of the Company is mainly attributable to the decline in turnover due to the following factors: the influenza outbreak in the PRC led to strong market demand for intravenous infusion solutions and other medicines in the first quarter of 2024, but the terminal sales volume of medicines has declined due to the absence of large-scale epidemic in the PRC and the control of medical insurance cost throughout the year ended 31 December 2025; the expansion of various forms of volume-based procurement (including the National Centralised Medicines Procurement and local alliance centralised procurement) and the intensification of domestic and international industry competition have brought about continuing price pressure; and turnover of Bromhexine Hydrochloride in ampoule injection decreased as it was no longer sold through National Centralized Medicines Procurement.공고 • Jan 28SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for adding 2ml specification for Composite Potassium Hydrogen Phosphate Injection from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Composite Pot potassium Hydrogen Phosphate In injection is a compound preparation which is mainly used for correction of hypophosphatemia in adult and child patients and for parenteral nutrition in adult and child patients when enteral nutrition is impossible, insufficient or prohibited. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Jan 05SSY Group Limited Obtains Approval for Drug Production and Registration for Perindopril Arginine and Amlodipine Besylate Tablets (III)The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Perindopril Arginine and Amlodipine Besylate Tablets (III) (perindopril arginine 10mg, amlodipine besylate 5mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Perindopril Arginines and AmlodipineBylate Tablet is a compound preparation which is mainly used in adult patients whose hypertension is not adequately controlled by monotherapy, or as an alternative therapy for primary hypertension which is under control by combination therapy with the same dose level of perindopril and amlodipine. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Nov 28SSY Group Limited Obtains Approval for Drug Production and Registration for Tolterodine Tartrate Sustained-Release Capsules (4mg)The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tolterodine Tartrate Sustained-release Capsules (4mg) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Tolterodine Tartrates Sustained-release Capsule is mainly used for treatment of overactive bladder.공고 • Oct 20SSY Group Limited Obtains Approval for Drug Production and Registration for Levlodipine Besilate TabletsThe board of directors of SSY Group Limited announced that the Group has obtained the approval s for drug production and registration for Levamlodipine Besilate Tablets (5mg and 2.5mg) from the National Medical Products Administration of China, both being under type 4 chemical drug and regarded as passing the consistency evaluation. Levamlodipine besilate Tablet is mainly used for the treatment of hypertension, chronic stable angina and vasospastic angina, which may be used alone or in combination with other drugs. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Sep 01SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Allopurinol Tablets (0.1g) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Allopurinol Tablet is mainly used for patients with primary or secondary gout, for patients with leukemia, lymphoma and malignant tumors undergoing treatment, and for the treatment of patients with recurrent calcium oxalate stones. As stated in the Company's announcement dated 28 April 2025, the Group's Allopurinol bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.공고 • Aug 19SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Morinidazole has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Morinidazole is a nitroimidazole antibiotic which is mainly used for the treatment of appendicitis and pelvic inflammatory disease caused by anaerobic bacteria. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Aug 18SSY Group Limited to Report First Half, 2025 Results on Aug 28, 2025SSY Group Limited announced that they will report first half, 2025 results on Aug 28, 2025공고 • Jul 10SSY Group Limited Obtains the Approvals for Drug Production and Registration for Potassium Chloride and Sodium Chloride Injection (500Ml and 250Ml) from the National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Pot potassium Chloride and Sodium Chloride Injection (500ml and 250ml) from the National Medical Products Administration of China, both being the second of such approvals for the PRC entities, under type 4 chemical drug and regarded as passing the consistency evaluation. Pot potassium Chloride and sodium Chloride Injection is mainly used for the treatment and prevention of hypokalemia, and for the treatment of frequent multifocal premature heart beat or tachycardia caused by digitalis poisoning. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Jul 08SSY Group Limited Announces Update on Innovative Drug DevelopmentThe board of directors of SSY Group Limited announce the updates on innovative drug development of the Group as follows: Progress on SYN045 tablets: As stated in the Company's announcement dated 3 April 2025, the Group's SYN045 tablets, a Type 1 new drug of chemical drug (a highly selective PGI2 receptor agonist with obvious anti-pulmonary hypertension effects on animals), has obtained approval from the National Medical Products Administration of China for adding three different specifications (10mg, 25mg and 50mg) for Phase I clinical trial. The Board announced that, recently, clinical trial of single administration of SYN045 tablets in 50mg and 100mg specifications and multiple administration of 25mg specifications have been completed. The research has shown good results in human pharmacokinetic characteristics and, as compared with drugs of the same drug target, significant improvements in safety and tolerability which are favourable in achieving long-term oral administration. As of now, a total of 18 invention patents has been submitted for SYN045 project, including 5 international invention patents (submitted for international pct applications) and 13 domestic invention patents (in which 5 invention patents related to compounds, crystal forms, preparations, etc. have been granted). Depending on the final results of the Phase I clinical trial, the Group is planning to commence the Phase IIa clinical trial in order to determine the dose-response relationship in the human body and explore the efficacy and safety in the body of patients. The Company will issue an announcement regarding the SYN045 tablets development as and when appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘Listing Rules’). Progress on other new drug development: The Board is also announced the updates on other new drug development of the Group as follows: Anti-epileptic innovative drug: Being a Type 1 anti-epileptic innovative drug project self-developed by the Group, its drug target is the potassium ion channel KCN Second Quarter /3. Currently, compound screening is commencing, and toxicity assessment is under preparation. Pain treatment innovative drug: Being a Type 1 innovative drug project self-developed by the Group for anti-diabetic peripheral neuropathic pain, its drug target is the adaptor-associated protein kinase 1 (AAK1). Currently, compound screening is commencing. New improved drug: The Group is currently commencing the research on improved formulations of three new drugs, two of which have been completed pharmacokinetic-based prescription studies and the remaining one is planned to submit an Investigational new drug (IND) application this year. With the plan of accelerating the innovative drug development and the progression of the above innovative drug projects, the Company will issue an announcement regarding the innovative drug development as and when appropriate in accordance with the Listing Rules.공고 • Jul 03SSY Group Limited Obtains Approval for Drug Production and Registration for Paracetamol GranulesThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Paracetamol Granules (0.1g each bag) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Paracetamol Granule is a drug for children of which the Group has obtained the exclusive approval among the PRC entities. It is mainly used for fever caused by common cold or influenza in children, and also for relief of mild to moderate pain. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Jun 30+ 1 more updateSSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Furosemide Tablets (20mg) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Furosemide Tablet is mainly used for the treatment of edema, hypertension, hypercalcemia and hyperkalemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and acute drug poisoning (such as barbiturate poisoning), and for the prevention of acute kidney failure.공고 • Jun 20+ 1 more updateSSY Group Limited Obtains Certificate of Suitability to the European Pharmacopoeia Monograph for European Union Bulk Pharmaceuticals Issued by the European Directorate for the Quality of Medicines and HealthcareThe board of directors of SSY Group Limited announced that the Group's caffeine has obtained the Certificate of Suitability to the European Pharmacopoeia monograph (CEP) for European Union bulk pharmaceuticals issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM) (the ‘CEP Certification’). The CEP Certification strictly examines the whole process of production technology, quality control, impurity research, etc. with standards being higher than those of ordinary international registrations, meeting the requirements of European and American pharmaceutical companies for using caffeine as a bulk pharmaceutical and being known as the ‘golden key’ for entering into the European and American markets. Caffeine is a key bulk pharmaceutical and additive which is widely used in the pharmaceutical, food and beverage industries. The Company believes that the CEP Certification will be beneficial to the Group in terms of international sales of caffeine, enhancement of products' international brand image and market share, and acceleration of upgrade from ‘product going overseas’ to ‘brand going overseas’.공고 • Jun 13SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tranexamic Acid and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Tranexamic Acid and sodium Chloride Injection is mainly used for the treatment of all kinds of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis.공고 • Jun 05SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Calcium Gluconate and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Cal calcium Gluconate and sodium Chloride Injection is mainly used for the treatment of acute hypocalcemia, magnesium poisoning and fluoride poisoning.공고 • May 30SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Low Calcium Peritoneal Dialysis Solution (Lactate -G4.25%) (2000ml, with 4.25% glucose). Low Calcium Peritoneal dialysis Solution (Lactate-G4.25%) is mainly used for patients with acute or chronic renal failure who need continuous ambulatory peritoneal dialysis treatment due to ineffective non-dialysis treatment. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Apr 23SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval s for drug production and registration for Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (I) (Dapagliflozin 10mg and Metformin Hydrochlorides 1,000mg) and Ibuprofen Arginine Granules (0.4g and 0.2g) from the National Medical Products Administration of China (the "NMPA"), both being under type 4 chemical drug and regarded as passing the consistency evaluation. Dapagliflozin & Metformin Hydrochloride Sustained-release Tablet (I) is mainly used for improving blood sugar control in adult patients with type 2 diabetes, and Ibuprofen Arinine Granule is mainly used for the following symptoms: toothache, dysmenorrhea, pain caused by trauma, joint and ligament pain, back pain, headache, neuralgia, and fever caused by influenza. The Board is also pleased to announce that the Group's Acipimox and Diprophylline have obtained the approvals for registration from the NMPA to become bulk drugs for the preparations on the market. Acipimox is mainly used in the treatment of hypertriglyceridemia and hypercholesterolemia, and Diprophylline is mainly used in The treatment of bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, etc. for relieving wheezing symptoms.공고 • Apr 10SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Felodipine has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Felodipine is mainly used for the treatment of mild to moderate essential hypertension and stable angina. As stated in the Company's announcement dated 30 March 2023, the Group's Felodipines/Felodipine II Sustained-release Controlled-release Tablets (5mg) have been selected in the tender of the National Centralised Medicines Procurement in the PRC. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Apr 01SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Arbidol Hydrochloride Tablets (50mg) from National Medical Products Administration of China, being under type 3 chemical drug, regarded as passing the consistency evaluation and the second of such approvals for the PRC entities. The Group also produces bulk drug of Arbidol Hydrochloride. Arbidol Hydrochloride Tablet is mainly used in the treatment of upper respiratory tract infections caused by influenza A and B viruses, Novel coronavirus pneumonia, and can be used in the treatment of infections caused by SARS coronavirus and avian influenza virus.공고 • Mar 31SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicardipine Hydrochloride Injection (10ml: 10mg) in form of ampoule from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. Nicardipine hydrochloride Injection in form of ampoule is mainly used for emergency treatment of abnormal hypertension during surgery and for hypertensive emergencies. As stated in the Company's announcement dated 5 March 2025, the Group's Nicardipine Hydrochlorides bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Board also announced that the Group has obtained the approval for drug production and registration for Sodium Bicarbonate Injection (10ml: 0.42g) in form of ampoul from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Sodium Bicarbonate Injection in form of ampoule is mainly used in the treatment of metabolic acidosis, alkalinization of urine and intravenous intoxication by certain drugs.공고 • Mar 28SSY Group Limited, Annual General Meeting, May 16, 2025SSY Group Limited, Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: rooms 4902-03, 49th floor, central plaza, 18 harbour road, wanchai, Hong Kong공고 • Mar 22SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Nimodipine has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nimodipine is a calcium channel blocker, which is mainly used for the treatment of ischemic cerebrovascular disease, migraine, sudden deafness, mild or moderate hypertension, and for the prevention of cerebral vasospasm caused by mild subarachnoid hemorrhage.공고 • Mar 21SSY Group Limited Obtains Approval for Drug Production and Registration for Voriconazole for Oral SuspensionThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Voriconazole for Oral Suspension (45g:3g) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Voriconazole for Oral suspension in oral dosage form, can be used in child aged 2 years or above and adult patients, and is mainly used in the treatment of various fungal infections, including invasive aspergillosis, candidemia and serious infections caused by Candida, Scedosporium and Fusarium, and for the prevention of invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Mar 18SSY Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025SSY Group Limited announced that they will report fiscal year 2024 results at 12:30 PM, China Standard Time on Mar 28, 2025공고 • Mar 14SSY Group Limited Obtains Approval for Drug Production and Registration for Epinephrine Hydrochloride Injection (1Ml:1Mg) from the National Medical Products Administration of ChinaSSY Group Limited announced that the Group has obtained the approval for drug production and registration for Epinephrine Hydrochloride Injection (1ml:1mg) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Epinephrine hydrochloride Injection is the main rescue drug for cardiopulmonary resuscitation in cardiac arrest, and can be used in the treatment of severe dyspnea caused by bronchospasm, rapid relief of anaphylaxis triggered by substances such as drugs, and prolongation of action time for infiltration anesthesia drugs. As stated in the Company's announcement dated 27 June 2024, the Group's Epinephrine bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Mar 05SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Nicardipine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nicardipine hydrochloride is mainly used for the treatment of hypertension.공고 • Feb 25SSY Group Limited Provides an Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tranexamic Acid Tablets (0.5g) from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Tranexamic Acid Tablet is mainly used for various kinds of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Acipimox Capsules (0.25g) from the NMPA, being under type 4 chemical drug, regarded as passing the consistency evaluation and the fourth of such approvals for the PRC entities. Acipimox Capsule is mainly used for reducing triglyceride levels in patients who do not respond adequately to other treatments (such as statins or fibrates).공고 • Feb 24SSY Group Limited Provides Update on Product DevelopmentSSY Group Limited announced that the Group's Piribedil has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Piribedil is mainly used for the treatment of Parkinson's disease and circulatory disturbance.공고 • Jan 20Ssy Group Limited Obtains Approval for Drug Production and Registration for Composite Potassium Hydrogen Phosphate Injection (5Ml) from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Composite Potassium Hydrogen Phosphate Injection (5ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug, regarded as passing the consistency evaluation and the first of such approval for the PRC entities. Composite Potassium Hydrogen Phosphate Injection is a compound preparation which is mainly used for correction of hypophosphatemia in adult and child patients and for parenteral nutrition in adult and child patients when enteral nutrition is impossible, insufficient or prohibited. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Vortioxetine Hydrobromide Tablets (5mg) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Vortioxetine Hydrobromide Tablet is mainly used for the treatment of depression in adults. As stated in the Company's announcement dated 27 December 2023, the Group's Vortioxetine Hydrobromide bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.공고 • Jan 08SSY Group Limited Obtains Approval for Drug Production and Registration for Vonoprazan Fumarate TabletsThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Vonoprazan Fumarate Tablets (20mg and 10mg) from National Medical Products Administration of China (the ‘NMPA’), being under type 4 chemical drug and regarded as passing the consistency evaluation. Vonoprazan Fumarate Tablet is mainly used for the treatment of reflux esophagitis. As stated in the Company's announcement dated 16 December 2024, the Group's Vonoprazan Fumarate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.공고 • Jan 06Ssy Group Limited Announces That the Benidipine Hydrochloride Obtained Approval for Registration from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group's Benidipine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Benidipine Hydrochloride is mainly used for the treatment of primary hypertension and angina pectoris.공고 • Dec 30SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Nikethamide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nikethamide is a central nervous system stimulant, which is mainly used for the treatment of central respiratory depression and respiratory depression of various causes.공고 • Dec 27+ 1 more updateSSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Furosemide Injection (2ml: 20mg). Furosemide Injection is mainly used for the treatment of various diseases with edema, hypertension, hyperkalemia and hypercalcemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and acute drug poisoning (such as barbiturate poisoning), and for the prevention of acute kidney failure.공고 • Dec 16SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announce that the Group's Vonoprazan Fumarate has obtained the approval for registration from the National Medical Products Administration of China (the ‘NMPA’) to become a bulk drug for the preparations on the market. Vonoprazan Fumarate is mainly used for the treatment of reflux esophagitis. In addition, the Board is also announced that the Group's Dronedarone Hydrochloride has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Dronedarone Hydrochloride is an antiarrhythmic drug. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Dec 02SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Compound Sodium Acetate and Glucose Injection (500ml and 200ml) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation, and was among the first three PRC manufacturers with approvals for such drug production. Compound sodium Acetate andGlucose Injection is mainly used in replenishing and maintaining water and electrolytes as well as supplying energy when oral administration is not possible or insufficient, and is the latest generation of sugar-containing sodium acetate balanced crystalloid. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Nov 27SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency EvaluationSSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Glycerol Fructose and Sodium Chloride Injection (250ml). Glycerol Fructose and Sodium Chloride Injection is mainly used for the treatment of acute or chronic intracranial pressure increase and cerebral edema which are caused by cerebrovascular disease, brain trauma, brain tumors, intracranial inflammation, etc.공고 • Nov 05SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)The board of directors (the "Board") of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Phenylephrine Hydrochloride Injection (1ml:10mg) from National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Phenylephrine Hydrochloride Injection is mainly used in maintaining blood pressure during treatment of shock and during anesthesia, and is also used in controlling paroxysmal supraventricular tachycardia. As stated in the Company's announcement dated 23 July 2024, the Group's Phenylephrine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.공고 • Oct 21SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of ChinaSSY Group Limited announced that the Group has obtained the approval for drug production and registration for Cycloserine Capsules (0.25g) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Cycloserine Capsule is mainly used for the treatment of active pulmonary tuberculosis and extrapulmonary tuberculosis which are caused by susceptible tuberculosis bacteria and after ineffective first-line anti-tuberculosis drug treatment. It can also be used for the treatment of acute urinary tract infections caused by susceptible gram-positive bacteria and gram-negative bacteria. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Lornoxicam for injection (8mg) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Lornoxicam for injection is mainly used for the short-term treatment of adults' acute pain from mild to moderate level which are not suitable for oral drug administration.공고 • Oct 14SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in ChinaSSY Group Limited announce that the Group's Cisatracurium Besilate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Cisatracurium Besilate is a muscle relaxant which is mainly used for muscle tension, sedation, general anesthesia during tracheal intubation and as an auxiliary medication to general anesthesia. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 18%After last week's 18% share price gain to HK$4.46, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 10x in the Pharmaceuticals industry in Hong Kong. Total returns to shareholders of 31% over the past three years.Recent Insider Transactions • Sep 25Chairman & CEO recently bought HK$4.8m worth of stockOn the 24th of September, Jiguang Qu bought around 1m shares on-market at roughly HK$3.87 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$21m worth in shares.공고 • Sep 09SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Nefopam Hydrochloride Injection (2ml: 20mg), being the first of such approval for the PRC entities. Nefopam Hydrochlorides Injection is mainly used for symptomatic treatment of acute pain, especially for postoperative pain.Recent Insider Transactions • Sep 04Chairman & CEO recently bought HK$1.5m worth of stockOn the 2nd of September, Jiguang Qu bought around 400k shares on-market at roughly HK$3.81 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$16m worth in shares.공고 • Sep 02SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicorandil Tablets (5mg) from National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. Nicorandil Tablet is mainly used in the treatment of angina. As stated in the Company's announcement dated 9 October 2023, the Group's Nicorandil bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.Reported Earnings • Aug 31First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)First half 2024 results: EPS: HK$0.23 (up from HK$0.21 in 1H 2023). Revenue: HK$3.34b (flat on 1H 2023). Net income: HK$685.7m (up 7.4% from 1H 2023). Profit margin: 21% (up from 19% in 1H 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Declared Dividend • Aug 30First half dividend increased to HK$0.08Dividend of HK$0.08 is 14% higher than last year. Ex-date: 12th September 2024 Payment date: 27th September 2024 Dividend yield will be 4.7%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (161% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공고 • Aug 28+ 1 more updateSSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024SSY Group Limited Announced the Interim Dividend of HKD 0.08 per share for the six months ended 30 June 2024. Ex-dividend date is on 12 September 2024 with Record date is on 20 September 2024. Payment date is on 27 September 2024.공고 • Aug 16SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024SSY Group Limited announced that they will report first half, 2024 results on Aug 28, 2024공고 • Aug 07SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Entacapone, Levodopa and Carbidopa Tablets (II) (Entacapone 200mg, Levodopa 100mg, Carbidopa 25mg) and Fluvoxamine maleate Tablets (100mg) from the National Medical Products Administration of China (the "NMPA"), both being under type 4 chemical drug and regarded as passing the consistency evaluation, with Entacapone, LevODopa and Carbidopa TableTS (II) being the first of such approval for the PRC entities. Entacapone, Levomopa and Carbidopa Tablet (II) are mainly used in adult patients with Parkinson's disease who have end-of-dose motor function fluctuations that cannot be controlled by levodopa/dopa decarboxylase (DDC) inhibitor therapy, and Fluvoxamine maleates Tablets are mainly used in the treatment of depression and obsessive-compulsive disorder. As stated in the Company's announcement dated 27 September 2023, the Group's Entacapone bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Board also announced that the Group has obtained the approval for drug production and registration for Lipid Emulsion (10%)/Amino Acids (15) and Glucose (20%) Injection (1000ml and 1500ml) from the NMPA, both being under type 4 chemical Drug, regarded as passing the consistency evaluation and the second of such approvals for the PRC entities. This three-ch chambers-bag injection is mainly used for parenteral nutrition when enteral nutrition is not feasible, insufficient or prohibited.Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to HK$3.69, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 8x in the Pharmaceuticals industry in Hong Kong. Total loss to shareholders of 20% over the past three years.공고 • Jul 23SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Phenylephrine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Phenylephrine Hydrochloride is mainly used in the treatment of low blood pressure caused by vasodilation during anesthesia.공고 • Jul 16SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Betahistine Mesilate Tablets (6mg) from National Medical Products Administration of China (the "NMPA"), being the first of such approval for the PRC entities, under type 4 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 27 June 2024, the Group's Betahistine Mesilate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Betahistine Mesilate Tablet is mainly used in the treatment of dizziness and lightheadedness associated with Meniere's disease, Meniere's syndrome and vertigo. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Jun 29SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Deferasirox has obtained the approval for registration from the National Medical Products Administration of China (the "NMPA") to become a bulk drug for the preparations on the market. Deferasirox is mainly used in patients with iron accumulation due to the need for long-term blood transfusions (such as thalassemia or other rare anemias patients). In addition, the Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Esmolol Hydrochloride Injection (10ml:0.1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Esmolol hydrochloride Injection is mainly used in supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Jun 24SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Etomidate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Etomidate is mainly used as an anesthetic drug, and is included in the list of controlled category II psychotropic drugs of China. Currently, the Group has held the psychotropic drugs production licences in China and complied with the relevant regulations on production and management. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Jun 18SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Esmolol Hydrochloride and Sodium Chloride Injection (100ml) from National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Esmolol Hydrochlorides and Sodium Chloride In injection is mainly used in supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Jun 08SSY Group Limited Announces Update on Product DevelopmentSSY Group Limited announced that the group's Butylphthalide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Butylphthalide is mainly used in the treatment of minor or moderate ischemic stroke (also known as brain attack).공고 • May 31+ 1 more updateSSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of ChinaThe board of directors of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") announced that the Group's Trelagliptin Succinate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the fourth of such approval in the PRC. Trelagliptin Succinate is mainly used for the treatment of type 2 diabetes with its tablets form being a long-acting inhibitor.공고 • May 29SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration ofChina has approved the addition of 50ml:4.2g specification and passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Sodium Bicarbonate Injection. Sodium Bicarbonate Injection is mainly used in the treatment of metabolic acidosis, alkalinization of urine, treatment of symptoms caused by hyperacidity and treatment of intravenous intoxication by certain drugs.공고 • May 28Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of ChinaSSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Ondansetron Hydrochloride Injection (4ml:8mg and 2ml:4mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Ondansetron Hydrochloride Injection is mainly used in the control of nausea and vomiting caused by cancer chemotherapy and radiation therapy, and in the prevention and treatment of post-surgery nausea and vomiting.Upcoming Dividend • May 14Upcoming dividend of HK$0.10 per shareEligible shareholders must have bought the stock before 21 May 2024. Payment date: 04 June 2024. Payout ratio is a comfortable 38% but the company is paying out more than the cash it is generating. Trailing yield: 3.5%. Lower than top quartile of Hong Kong dividend payers (7.5%). In line with average of industry peers (3.3%).공고 • Apr 03SSY Group Limited Provides Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Cefuroxime Axetil for Suspension (0.25g and 0.125g) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation, with 0.25g specification being the first and 0.125g specification being the second of such approvals for the PRC entities. Cefuroxime Axetil for Suspension is mainly used in the treatment of infectious diseases caused by susceptible bacteria. In addition, the Board announced that the Group has obtained the approvals for drug production and registration for Lidocaine Hydrochloride Injection (20ml:0.4g, 10ml:0.2g and 5ml:0.1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 23 January 2024, the Group's Lidocaine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Lidocaine Hydrochloride Injection is a local anesthesia and antiarrhythmic drug which is mainly used in infiltration anesthesia, epidural anesthesia, surface anesthesia and nerve conduction block.Recent Insider Transactions • Mar 29Chairman & CEO recently bought HK$2.5m worth of stockOn the 28th of March, Jiguang Qu bought around 500k shares on-market at roughly HK$4.91 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$24m worth in shares.공고 • Mar 28SSY Group Limited, Annual General Meeting, May 17, 2024SSY Group Limited, Annual General Meeting, May 17, 2024, at 14:00 China Standard Time. Location: Rooms 4902-03, 49th Floor, Central Plaza, 18 Harbour Road Wanchai Hong KongReported Earnings • Mar 28Full year 2023 earnings released: EPS: HK$0.44 (vs HK$0.38 in FY 2022)Full year 2023 results: EPS: HK$0.44 (up from HK$0.38 in FY 2022). Revenue: HK$6.46b (flat on FY 2022). Net income: HK$1.32b (up 17% from FY 2022). Profit margin: 20% (up from 18% in FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.공고 • Mar 27SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024SSY Group Limited announced Final Dividend for the year ended 31 December 2023 of HKD 0.1 per share with Ex-dividend date 21 May 2024; Record date 22 May 2024 & Payment date 04 June 2024.공고 • Mar 21SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Benserazide hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Berazide hydrochloride is a decarboxylase inhibitor, which is mainly used in combination with Levodopa for the treatment of Parkinson's disease.공고 • Mar 16SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024SSY Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024공고 • Mar 02SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Nicorandil for Injection is a type of lyophilized powder for injection. It is the third approved lyophilized powder for injection products of the Group, and is mainly used for the treatment of unstable angina.공고 • Mar 01SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the MarketThe board of directors of SSY Group Limited announced that the Group's Norepinephrine bitartrate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Norepinephrine bitartrate is an adrenergic receptors agonist, which is mainly used clinically in anti-shock by causing extreme contraction of blood vessels to increase blood pressure and coronary blood flow as well as by strengthening myocardial contraction and increasing cardiac output.공고 • Feb 28SSY Group Limited Receives Approval for Gliclazide TabletThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Gliclazide Tablets (80mg). Gliclazide Tablet is mainly used in adult patients with type 2 diabetes when dietary control, exercise, and weight loss are not enough to control blood sugar level.공고 • Feb 24SSY Group Limited Provides Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Sodium Bicarbonate Ringer's Injection (500ml) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Sodium Bicarbonate Ringer's Injection is mainly used for replenishing extracellular fluid when circulating blood volume and interstitial fluid decrease, and for correction of metabolic acidosis.공고 • Feb 19SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Propofol Medium and Long Chain Fat Emulsion Injection (20ml: 0.2g and 10ml: 0.1g) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and being the first approved fat emulsion ampoule injection product of the Group. Propofol Medium and Long Chain Fat Emulsion Injection is a short-acting intravenous anesthetic for general anesthesia. It is mainly used for induction and maintenance of general anesthesia, sedation of patients undergoing diagnostic procedures and surgeries, and sedation of patients receiving assisted ventilation treatment.공고 • Jan 31SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Isoprenaline hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the second of such approval in the PRC.공고 • Jan 24SSY Group Limited Provides Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Lidocaine hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Lidocaine hydro chloride is a local anesthesia and antiarrhythmic drug. It is mainly used in infiltration anesthesia, epidural anesthesia, surface anesthesia and nerve conduction block.공고 • Jan 19+ 1 more updateSSY Group Limited Appoints Liu Wenjun as Non-Executive DirectorThe board (the "Board") of directors (the "Director(s)") of SSY Group Limited (the "Company") announced that Mr. Liu Wenjun ("Mr. Liu") has been appointed as a non-executive Director of the Company with effect from 19 January 2024. Mr. Liu Wenjun, aged 52, currently serves as the general manager of the Xindu Base of Sichuan Kelun Pharmaceutical Company Limited ("Sichuan Kelun", a substantial shareholder of the Company interested in approximately 20.43% of the issued share capital of the Company), a position he has taken since 2013. He was the general manager of Kunming Nanjiang Pharmaceutical Co. Ltd. from 2005 to 2013. He served as a workshop supervisor of Sichuan Kelun from 2002 to 2005, and a technician at the Sichuan Antibiotics Laboratory of the National Medical Products Administration from 1996 to 2002. Mr. Liu graduated from Chengdu University of Traditional Chinese Medicine with a Bachelor of Science degree and holds the qualification of a Senior Engineer in the People's Republic of China.공고 • Jan 17Ssy Group Limited Provides Update on Product DevelopmentSSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Magnesium Sulfate Injection (20ml: 10g, 10ml: 5g and 2ml: 1g) and Vortioxetine Hydrobromide Tablets (10mg) from the National Medical Products Administration of China, being under type 3 chemical drug and type 4 chemical drug respectively, and regarded as passing the consistency evaluation. As an anticonvulsant drug, Magnesium Sulfate Injection is a mainly used in pregnancy-induced hyper-tension for the treatment of pre-eclampsia and eclampsia by reducing blood pressure. Vortioxetine Hydrobromide Tablets is mainly used for the treatment of depression in adults.공고 • Jan 10SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Chlorphenamine Maleate Injection (2ml: 20mg and 1ml: 10mg), in which the 2ml: 20mg specification being the first and 1ml: 10mg specification being the second of respective approvals for the PRC entities. Chlorphenamine Maleate Injection is mainly used in the treatment of allergic rhinitis, and can also be used for colds or sinusitis, mucocutaneous allergy, and control of drug eruption and contact dermatitis.공고 • Jan 05SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Ropivacaine Hydrochloride and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approval for the PRC entities. Ropivacaine Hydro chloride and Sodium Chloride injection is mainly used in local or regional anesthesia and acute pain management for surgery. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.공고 • Dec 27SSY Group Limited Provides Update on Product DevelopmentThe board of directors (the "Board") of SSY Group Limited announce that the Group's Vortioxetine hydrobromide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Vortioxetine hydrobromide is a 5-hydroxytryptamine (5-HT) reuptake inhibitor, and is an agonist, partial agonist or antagonist of certain types of 5-HT receptors. It is mainly used in the treatment of major depressive disorder (MDD) in adults.Recent Insider Transactions • Dec 06Chairman & CEO recently bought HK$4.7m worth of stockOn the 5th of December, Jiguang Qu bought around 1m shares on-market at roughly HK$4.74 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$24m worth in shares.공고 • Dec 01SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tedizolid Phosphate Tablets (200mg) from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 11 April 2023, the Group's Tedizolid phosphate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Tedizolid Phosphate Tablet is mainly used in the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of Gram-positive bacteria (including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus, and Enterococcus facadeecalis). This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.이익 및 매출 성장 예측SHSC:2005 - 애널리스트 향후 추정치 및 과거 재무 데이터 (HKD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20286,245937N/A1,244112/31/20275,473702N/A934212/31/20264,878587N/A1,365212/31/20254,165471330635N/A9/30/20254,373565112483N/A6/30/20254,582659-105332N/A3/31/20255,177860-64411N/A12/31/20245,7731,061-22491N/A9/30/20246,1211,21391638N/A6/30/20246,4691,366205785N/A3/31/20246,4661,342259855N/A12/31/20236,4631,319313926N/A9/30/20236,4131,255406965N/A6/30/20236,3631,1914991,004N/A3/31/20236,3981,157407869N/A12/31/20226,4341,123316734N/A9/30/20226,3761,101318752N/A6/30/20226,3181,080321769N/A3/31/20225,838933314733N/A12/31/20215,357786307696N/A9/30/20215,139713205605N/A6/30/20214,921641102514N/A3/31/20214,591626143509N/A12/31/20204,261612183505N/A9/30/20204,177723140558N/A6/30/20204,09383597611N/A3/31/20204,364985-47628N/A12/31/20194,6361,136-190646N/A9/30/20194,5251,075N/A629N/A6/30/20194,4141,014N/A612N/A3/31/20194,297963N/A791N/A12/31/20184,181912N/A970N/A9/30/20184,012867N/A906N/A6/30/20183,844822N/A843N/A3/31/20183,460743N/A698N/A12/31/20173,076665N/A552N/A9/30/20172,827616N/A676N/A6/30/20172,577567N/A799N/A3/31/20172,469528N/A743N/A12/31/20162,361490N/A686N/A9/30/20162,315426N/A579N/A6/30/20162,270363N/A472N/A3/31/20162,246383N/A517N/A12/31/20152,222403N/A563N/A9/30/20152,189443N/A326N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 2005 의 연간 예상 수익 증가율(21.2%)이 saving rate(3%)보다 높습니다.수익 vs 시장: 2005 의 연간 수익(21.2%)이 Hong Kong 시장(12.1%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 2005 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 2005 의 수익(연간 13%)이 Hong Kong 시장(연간 8.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 2005 의 수익(연간 13%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 2005의 자본 수익률은 3년 후 11.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/30 21:40종가2026/07/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SSY Group Limited는 17명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ying ShaoBofA Global ResearchYanyin ZhuChina International Capital Corporation LimitedZhengyang WangCitic Securities Co., Ltd.14명의 분석가 더 보기
공고 • Feb 16SSY Group Limited Provides Group Earnings Guidance for the Year Ended 31 December 2025SSY Group Limited provided group earnings guidance for the year ended 31 December 2025. The board of directors of the Company (the "Board") informed shareholders of the Company (the "Shareholders") and potential investors that, based on the information currently available to the Board and after preliminary assessment of the Group's unaudited management accounts for the year ended 31 December 2025, the Board preliminarily estimates that the Group is expected to record a reduction in profit attributable to equity shareholders of the Company for the year ended 31 December 2025 in the range of 45% to 60% as compared to profit attributable to equity shareholders of the Company of HKD 1,061,150,000 for the year ended 31 December 2024. The estimated reduction in the profit attributable to equity shareholders of the Company is mainly attributable to the decline in turnover due to the following factors: the influenza outbreak in the PRC led to strong market demand for intravenous infusion solutions and other medicines in the first quarter of 2024, but the terminal sales volume of medicines has declined due to the absence of large-scale epidemic in the PRC and the control of medical insurance cost throughout the year ended 31 December 2025; the expansion of various forms of volume-based procurement (including the National Centralised Medicines Procurement and local alliance centralised procurement) and the intensification of domestic and international industry competition have brought about continuing price pressure; and turnover of Bromhexine Hydrochloride in ampoule injection decreased as it was no longer sold through National Centralized Medicines Procurement.
공고 • Jul 23SSY Group Limited Announces Update on Drug Approvals Enhancing Diversified Pharmaceutical Product PortfolioThe board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for the following four products from National Medical Products Administration of China, all being under type 4 chemical drug and regarded as passing the consistency evaluation. Hemofiltration Replacement Fluid of Sodium Citrate (5000ml): This product is mainly used as a replacement fluid in continuous renal replacement therapy (CRRT) with local citrate anticoagulation, and is particularly suitable for patients such as those with an increased risk of bleeding who are not advised for systemic anticoagulation with heparin. Compared to clinical mainstream split citrate formula (bicarbonate replacement fluid combined with a separate sodium citrate anticoagulant), this product has significant clinical advantages and a promising market prospect. The Group is actively developing large-volume injections such as hemofiltration replacement solutions and peritoneal dialysis solutions, further improving its product portfolio. Benidipine Hydrochloride Tablets (4mg): This product is mainly used for the treatment of primary hypertension and angina pectoris. The Group has established a comprehensive hypertension product portfolio, covering 2nd and 3rd generation calcium channel blockers, ACE inhibitors, -receptor blockers, and multiple single- tablet compound preparations, along with intravenous emergency antihypertensive drugs used in intensive care unit (ICU). Among which, the Group's Benidipine Hydrochloride Tablets in 8mg specification has been approved for market and selected in the tender result of the eleventh batch of the National Centralised Medicines Procurement. With the approval of its 4mg specification, the initial low-dose treatment needs for hypertension can be fully met, forming a complete dose gradient of "initial titration 4mg + maintenance therapy 8mg". Polyvinyl Alcohol Eye Drops 1.4% (0.4ml: 5.6mg): This product is mainly used as a lubricant for prevention or treatment of irritation symptoms such as dry eyes, foreign matter sensation and eye fatigue, or for improvement of eye dryness symptoms. Polyvinyl Alcohol Eye Drop is in single-dose packaging, preservative-free, and is an OTC product for office workers experiencing eye strain, people spending long time at screens or with sensitive ocular surfaces for their immediate relief of dry eyes. The Group has a strategic layout in ophthalmic drug segment with single-dose and preservative-free formulations, and has built a product portfolio including anti-infectives, anti-allergens, intraocular pressure lowering, artificial tears and ocular anti-inflammatory, forming a dual-channel layout of in-hospital prescription drugs and retail OTC. Fat Emulsion, Amino Acids (17) and Glucose (19%) Injection (1540ml and 1026ml): This product is mainly used for adult patients who are unable, with impaired function or not advised for receiving nutrition orally or enterally. This product is a complex three-chamber bag preparation for parenteral nutrition with high technological barriers. It is mainly used for intravenous nutritional support in adult patients after surgery, those with tumors or in ICU. The newly approved 1540ml and 1026ml specifications can meet the individualised clinical needs of patients with different weights and energy requirements. The Group is systematically developing a parenteral nutrition product platform covering premixed three-chamber bag all-in-one preparations, nutrients, vitamins, trace elements and electrolyte supplements. This approval further enhances the Group's high-end intravenous nutrition product portfolio, creating synergy with its basic infusion, amino acid and fat emulsion series, and will bring a positive effect on its expansion into the perioperative and critical care nutrition markets.
공고 • Jul 21SSY Group Limited Obtains Approval For Registration Of Gadobutrol As Bulk Drug For Market PreparationsSSY Group Limited has announced that the Group’s Gadobutrol has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Gadobutrol is a magnetic resonance imaging contrast agent used for adults and children of all ages (including full-term newborns), and is mainly used for contrast-enhanced magnetic resonance imaging (CE-MRI) examinations of lesions in various parts of the body (including the brain and spinal cord), as well as contrast-enhanced magnetic resonance angiography (CE-MRA) examinations of various parts of the body. Gadobutrol, as a new generation of magnetic resonance imaging contrast agent with macrocyclic structure, is more stable and safer than Gadopentetate Dimeglumine with linear structure, offering advantage for clinical substitution. Gadolinium is a rare-earth metal, and the Group is actively developing an integrated business of bulk drugs and injection preparations under Gadolinium category.
공고 • Jul 18Ssy Group Limited Obtains Approval for Drug Production and Registration of Choline Fenofibrate Sustained-Release CapsulesSSY Group Limited has obtained the approval for drug production and registration for Choline Fenofibrate Sustained-release Capsules (135mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Choline Fenofibrate Sustained-release Capsule is mainly used in adults with controlled diets for lowering triglyceride levels in patients with severe hypertriglyceridemia, and for treatment of patients with primary hypercholesterolemia or mixed dyslipidemia. As compared to traditional fenofibrate, choline fenofibrate has a direct effect, a lower liver and kidney burden, can be taken without dietary restrictions and safely combined with statins drug, making it a high-end triglyceride-lowering product of next generation with clinical necessity.
공고 • Jul 13SSY Group Limited Obtains Approval for Registration of Baloxavir Marboxil as Bulk Drug in ChinaSSY Group Limited announced that the Group’s Baloxavir Marboxil has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Baloxavir Marboxil is mainly used for the treatment of influenza A and influenza B.
공고 • Jul 10+ 1 more updateSSY Group Limited Announces Inclusion of 95 Types of Products in National Essential Medicines List (2026 Edition)SSY Group Limited announced that a total of 95 types (with 141 specifications) of products of the Group have been included in the National Essential Medicines List (2026 Edition) of China, including the newly added 32 types (with 37 specifications), namely Glucose & Sodium Chloride Injection, Levofloxacin Lactate & Sodium Chloride Injection, Levofloxacin & Sodium Chloride Injection, Sodium Bicarbonate Injection, Fluconazole Tablets, Gliclazide Tablets, Clear Heat & Detox Oral Liquid, Potassium Chloride Injection, Mecobalamin Injection, Ambroxol Hydrochloride Injection, Bromhexine Hydrochloride Injection, Medium/Long Chain Fat Emulsion Injection, Azithromycin for Injection, Paracetamol Tablets, Azithromycin for Suspension, Ipratropium Bromide Solution for Inhalation, Lurasidone Hydrochloride Tablets, Urapidil Hydrochloride Injection, Citicoline Sodium Injection, Oseltamivir Phosphate for Suspension, Aminophylline Injection, Magnesium Sulfate Injection, Cefuroxime Axetil for Suspension, Ondansetron Hydrochloride Injection, Entacapone Tablets, Isosorbide Dinitrate Injection, Betahistine Mesilate Tablets, Norepinephrine Bitartrate Injection, Levamlodipine Besilate Tablets, Levofloxacin Eye Drops, Propafenone Hydrochloride Injection and Metoclopramide Hydrochloride Injection. The List will become effective on 1 September 2026, which is expected to have a positive impact on the growth and business development of the Group. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Jun 24SSY Group Limited Obtains Approval for Drug Production and Registration for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation SolutionSSY Group Limited has obtained the approval for drug production and registration for Safinamide Mesylate Tablets (100mg and 50mg) from National Medical Products Administration of China (the NMPA), being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Safinamide Mesylate Tablet is mainly used in combination therapy for adult patients with primary Parkinson’s disease and symptoms fluctuation, in combination with other drugs for Parkinson’s disease such as levodopa. As stated in the Company’s announcement dated 26 May 2026, the Group’s Safinamide Mesylate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Group has obtained the approval for drug production and registration for Procaterol Hydrochloride Inhalation Solution (0.3ml: 30µg) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Procaterol Hydrochloride Inhalation Solution is mainly used in the relief of various symptoms based on airflow limitation in bronchial asthma, chronic bronchitis and emphysema.
공고 • Jun 09Ssy Group Limited Obtains Approval to Become Market Authorization Holder of Ceftizoxime Sodium for InjectionSSY Group Limited has obtained the approval from the National Medical Products Administration of China for the change to become the market authorization holder of Ceftizoxime Sodium for Injection (1g and 0.5g). Ceftizoxime Sodium for Injection is mainly used for the treatment of (1) lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections caused by susceptible bacteria; (2) meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae; and (3) uncomplicated gonorrhea. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Guangce Jiang was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 22Ssy Group Limited Announces Furosemide Obtains Approval for Registration in ChinaThe board of directors of SSY Group Limited is announcing that the Group’s Furosemide has obtained the approval for registration from the National Medical Products Administration of China to become bulk drug for the preparations on the market. As stated in the Company’s announcements dated 30 June 2025 and 27 December 2024 respectively, the Group has obtained the approvals for drug production and registration for Furosemide Tablet and Furosemide Injection from the NMPA. Furosemide is mainly used for the treatment of various diseases with edema, hypertension, hyperkalemia and hypercalcemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and acute drug poisoning (such as barbiturate poisoning), and for the prevention of acute kidney failure. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Mar 27SSY Group Limited, Annual General Meeting, May 15, 2026SSY Group Limited, Annual General Meeting, May 15, 2026, at 14:00 China Standard Time. Location: rooms 4902-03, 49th floor, central plaza, 18 harbour road, wanchai., Hong Kong
공고 • Mar 17SSY Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026SSY Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026
공고 • Mar 06Ssy Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Calcium Levofolinate for Injection (25mg) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Calcium Levofolinate for Injection is mainly used for the treatment of gastric cancer and colorectal cancer in combination with 5-fluorouracil.
공고 • Feb 16SSY Group Limited Provides Group Earnings Guidance for the Year Ended 31 December 2025SSY Group Limited provided group earnings guidance for the year ended 31 December 2025. The board of directors of the Company (the "Board") informed shareholders of the Company (the "Shareholders") and potential investors that, based on the information currently available to the Board and after preliminary assessment of the Group's unaudited management accounts for the year ended 31 December 2025, the Board preliminarily estimates that the Group is expected to record a reduction in profit attributable to equity shareholders of the Company for the year ended 31 December 2025 in the range of 45% to 60% as compared to profit attributable to equity shareholders of the Company of HKD 1,061,150,000 for the year ended 31 December 2024. The estimated reduction in the profit attributable to equity shareholders of the Company is mainly attributable to the decline in turnover due to the following factors: the influenza outbreak in the PRC led to strong market demand for intravenous infusion solutions and other medicines in the first quarter of 2024, but the terminal sales volume of medicines has declined due to the absence of large-scale epidemic in the PRC and the control of medical insurance cost throughout the year ended 31 December 2025; the expansion of various forms of volume-based procurement (including the National Centralised Medicines Procurement and local alliance centralised procurement) and the intensification of domestic and international industry competition have brought about continuing price pressure; and turnover of Bromhexine Hydrochloride in ampoule injection decreased as it was no longer sold through National Centralized Medicines Procurement.
공고 • Jan 28SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for adding 2ml specification for Composite Potassium Hydrogen Phosphate Injection from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Composite Pot potassium Hydrogen Phosphate In injection is a compound preparation which is mainly used for correction of hypophosphatemia in adult and child patients and for parenteral nutrition in adult and child patients when enteral nutrition is impossible, insufficient or prohibited. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Jan 05SSY Group Limited Obtains Approval for Drug Production and Registration for Perindopril Arginine and Amlodipine Besylate Tablets (III)The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Perindopril Arginine and Amlodipine Besylate Tablets (III) (perindopril arginine 10mg, amlodipine besylate 5mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Perindopril Arginines and AmlodipineBylate Tablet is a compound preparation which is mainly used in adult patients whose hypertension is not adequately controlled by monotherapy, or as an alternative therapy for primary hypertension which is under control by combination therapy with the same dose level of perindopril and amlodipine. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Nov 28SSY Group Limited Obtains Approval for Drug Production and Registration for Tolterodine Tartrate Sustained-Release Capsules (4mg)The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tolterodine Tartrate Sustained-release Capsules (4mg) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Tolterodine Tartrates Sustained-release Capsule is mainly used for treatment of overactive bladder.
공고 • Oct 20SSY Group Limited Obtains Approval for Drug Production and Registration for Levlodipine Besilate TabletsThe board of directors of SSY Group Limited announced that the Group has obtained the approval s for drug production and registration for Levamlodipine Besilate Tablets (5mg and 2.5mg) from the National Medical Products Administration of China, both being under type 4 chemical drug and regarded as passing the consistency evaluation. Levamlodipine besilate Tablet is mainly used for the treatment of hypertension, chronic stable angina and vasospastic angina, which may be used alone or in combination with other drugs. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Sep 01SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Allopurinol Tablets (0.1g) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Allopurinol Tablet is mainly used for patients with primary or secondary gout, for patients with leukemia, lymphoma and malignant tumors undergoing treatment, and for the treatment of patients with recurrent calcium oxalate stones. As stated in the Company's announcement dated 28 April 2025, the Group's Allopurinol bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.
공고 • Aug 19SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Morinidazole has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Morinidazole is a nitroimidazole antibiotic which is mainly used for the treatment of appendicitis and pelvic inflammatory disease caused by anaerobic bacteria. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Aug 18SSY Group Limited to Report First Half, 2025 Results on Aug 28, 2025SSY Group Limited announced that they will report first half, 2025 results on Aug 28, 2025
공고 • Jul 10SSY Group Limited Obtains the Approvals for Drug Production and Registration for Potassium Chloride and Sodium Chloride Injection (500Ml and 250Ml) from the National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Pot potassium Chloride and Sodium Chloride Injection (500ml and 250ml) from the National Medical Products Administration of China, both being the second of such approvals for the PRC entities, under type 4 chemical drug and regarded as passing the consistency evaluation. Pot potassium Chloride and sodium Chloride Injection is mainly used for the treatment and prevention of hypokalemia, and for the treatment of frequent multifocal premature heart beat or tachycardia caused by digitalis poisoning. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Jul 08SSY Group Limited Announces Update on Innovative Drug DevelopmentThe board of directors of SSY Group Limited announce the updates on innovative drug development of the Group as follows: Progress on SYN045 tablets: As stated in the Company's announcement dated 3 April 2025, the Group's SYN045 tablets, a Type 1 new drug of chemical drug (a highly selective PGI2 receptor agonist with obvious anti-pulmonary hypertension effects on animals), has obtained approval from the National Medical Products Administration of China for adding three different specifications (10mg, 25mg and 50mg) for Phase I clinical trial. The Board announced that, recently, clinical trial of single administration of SYN045 tablets in 50mg and 100mg specifications and multiple administration of 25mg specifications have been completed. The research has shown good results in human pharmacokinetic characteristics and, as compared with drugs of the same drug target, significant improvements in safety and tolerability which are favourable in achieving long-term oral administration. As of now, a total of 18 invention patents has been submitted for SYN045 project, including 5 international invention patents (submitted for international pct applications) and 13 domestic invention patents (in which 5 invention patents related to compounds, crystal forms, preparations, etc. have been granted). Depending on the final results of the Phase I clinical trial, the Group is planning to commence the Phase IIa clinical trial in order to determine the dose-response relationship in the human body and explore the efficacy and safety in the body of patients. The Company will issue an announcement regarding the SYN045 tablets development as and when appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘Listing Rules’). Progress on other new drug development: The Board is also announced the updates on other new drug development of the Group as follows: Anti-epileptic innovative drug: Being a Type 1 anti-epileptic innovative drug project self-developed by the Group, its drug target is the potassium ion channel KCN Second Quarter /3. Currently, compound screening is commencing, and toxicity assessment is under preparation. Pain treatment innovative drug: Being a Type 1 innovative drug project self-developed by the Group for anti-diabetic peripheral neuropathic pain, its drug target is the adaptor-associated protein kinase 1 (AAK1). Currently, compound screening is commencing. New improved drug: The Group is currently commencing the research on improved formulations of three new drugs, two of which have been completed pharmacokinetic-based prescription studies and the remaining one is planned to submit an Investigational new drug (IND) application this year. With the plan of accelerating the innovative drug development and the progression of the above innovative drug projects, the Company will issue an announcement regarding the innovative drug development as and when appropriate in accordance with the Listing Rules.
공고 • Jul 03SSY Group Limited Obtains Approval for Drug Production and Registration for Paracetamol GranulesThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Paracetamol Granules (0.1g each bag) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Paracetamol Granule is a drug for children of which the Group has obtained the exclusive approval among the PRC entities. It is mainly used for fever caused by common cold or influenza in children, and also for relief of mild to moderate pain. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Jun 30+ 1 more updateSSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Furosemide Tablets (20mg) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Furosemide Tablet is mainly used for the treatment of edema, hypertension, hypercalcemia and hyperkalemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and acute drug poisoning (such as barbiturate poisoning), and for the prevention of acute kidney failure.
공고 • Jun 20+ 1 more updateSSY Group Limited Obtains Certificate of Suitability to the European Pharmacopoeia Monograph for European Union Bulk Pharmaceuticals Issued by the European Directorate for the Quality of Medicines and HealthcareThe board of directors of SSY Group Limited announced that the Group's caffeine has obtained the Certificate of Suitability to the European Pharmacopoeia monograph (CEP) for European Union bulk pharmaceuticals issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM) (the ‘CEP Certification’). The CEP Certification strictly examines the whole process of production technology, quality control, impurity research, etc. with standards being higher than those of ordinary international registrations, meeting the requirements of European and American pharmaceutical companies for using caffeine as a bulk pharmaceutical and being known as the ‘golden key’ for entering into the European and American markets. Caffeine is a key bulk pharmaceutical and additive which is widely used in the pharmaceutical, food and beverage industries. The Company believes that the CEP Certification will be beneficial to the Group in terms of international sales of caffeine, enhancement of products' international brand image and market share, and acceleration of upgrade from ‘product going overseas’ to ‘brand going overseas’.
공고 • Jun 13SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tranexamic Acid and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Tranexamic Acid and sodium Chloride Injection is mainly used for the treatment of all kinds of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis.
공고 • Jun 05SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Calcium Gluconate and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Cal calcium Gluconate and sodium Chloride Injection is mainly used for the treatment of acute hypocalcemia, magnesium poisoning and fluoride poisoning.
공고 • May 30SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Low Calcium Peritoneal Dialysis Solution (Lactate -G4.25%) (2000ml, with 4.25% glucose). Low Calcium Peritoneal dialysis Solution (Lactate-G4.25%) is mainly used for patients with acute or chronic renal failure who need continuous ambulatory peritoneal dialysis treatment due to ineffective non-dialysis treatment. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Apr 23SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval s for drug production and registration for Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (I) (Dapagliflozin 10mg and Metformin Hydrochlorides 1,000mg) and Ibuprofen Arginine Granules (0.4g and 0.2g) from the National Medical Products Administration of China (the "NMPA"), both being under type 4 chemical drug and regarded as passing the consistency evaluation. Dapagliflozin & Metformin Hydrochloride Sustained-release Tablet (I) is mainly used for improving blood sugar control in adult patients with type 2 diabetes, and Ibuprofen Arinine Granule is mainly used for the following symptoms: toothache, dysmenorrhea, pain caused by trauma, joint and ligament pain, back pain, headache, neuralgia, and fever caused by influenza. The Board is also pleased to announce that the Group's Acipimox and Diprophylline have obtained the approvals for registration from the NMPA to become bulk drugs for the preparations on the market. Acipimox is mainly used in the treatment of hypertriglyceridemia and hypercholesterolemia, and Diprophylline is mainly used in The treatment of bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, etc. for relieving wheezing symptoms.
공고 • Apr 10SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Felodipine has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Felodipine is mainly used for the treatment of mild to moderate essential hypertension and stable angina. As stated in the Company's announcement dated 30 March 2023, the Group's Felodipines/Felodipine II Sustained-release Controlled-release Tablets (5mg) have been selected in the tender of the National Centralised Medicines Procurement in the PRC. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Apr 01SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Arbidol Hydrochloride Tablets (50mg) from National Medical Products Administration of China, being under type 3 chemical drug, regarded as passing the consistency evaluation and the second of such approvals for the PRC entities. The Group also produces bulk drug of Arbidol Hydrochloride. Arbidol Hydrochloride Tablet is mainly used in the treatment of upper respiratory tract infections caused by influenza A and B viruses, Novel coronavirus pneumonia, and can be used in the treatment of infections caused by SARS coronavirus and avian influenza virus.
공고 • Mar 31SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicardipine Hydrochloride Injection (10ml: 10mg) in form of ampoule from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. Nicardipine hydrochloride Injection in form of ampoule is mainly used for emergency treatment of abnormal hypertension during surgery and for hypertensive emergencies. As stated in the Company's announcement dated 5 March 2025, the Group's Nicardipine Hydrochlorides bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Board also announced that the Group has obtained the approval for drug production and registration for Sodium Bicarbonate Injection (10ml: 0.42g) in form of ampoul from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Sodium Bicarbonate Injection in form of ampoule is mainly used in the treatment of metabolic acidosis, alkalinization of urine and intravenous intoxication by certain drugs.
공고 • Mar 28SSY Group Limited, Annual General Meeting, May 16, 2025SSY Group Limited, Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: rooms 4902-03, 49th floor, central plaza, 18 harbour road, wanchai, Hong Kong
공고 • Mar 22SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Nimodipine has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nimodipine is a calcium channel blocker, which is mainly used for the treatment of ischemic cerebrovascular disease, migraine, sudden deafness, mild or moderate hypertension, and for the prevention of cerebral vasospasm caused by mild subarachnoid hemorrhage.
공고 • Mar 21SSY Group Limited Obtains Approval for Drug Production and Registration for Voriconazole for Oral SuspensionThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Voriconazole for Oral Suspension (45g:3g) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Voriconazole for Oral suspension in oral dosage form, can be used in child aged 2 years or above and adult patients, and is mainly used in the treatment of various fungal infections, including invasive aspergillosis, candidemia and serious infections caused by Candida, Scedosporium and Fusarium, and for the prevention of invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Mar 18SSY Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025SSY Group Limited announced that they will report fiscal year 2024 results at 12:30 PM, China Standard Time on Mar 28, 2025
공고 • Mar 14SSY Group Limited Obtains Approval for Drug Production and Registration for Epinephrine Hydrochloride Injection (1Ml:1Mg) from the National Medical Products Administration of ChinaSSY Group Limited announced that the Group has obtained the approval for drug production and registration for Epinephrine Hydrochloride Injection (1ml:1mg) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Epinephrine hydrochloride Injection is the main rescue drug for cardiopulmonary resuscitation in cardiac arrest, and can be used in the treatment of severe dyspnea caused by bronchospasm, rapid relief of anaphylaxis triggered by substances such as drugs, and prolongation of action time for infiltration anesthesia drugs. As stated in the Company's announcement dated 27 June 2024, the Group's Epinephrine bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Mar 05SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Nicardipine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nicardipine hydrochloride is mainly used for the treatment of hypertension.
공고 • Feb 25SSY Group Limited Provides an Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tranexamic Acid Tablets (0.5g) from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Tranexamic Acid Tablet is mainly used for various kinds of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Acipimox Capsules (0.25g) from the NMPA, being under type 4 chemical drug, regarded as passing the consistency evaluation and the fourth of such approvals for the PRC entities. Acipimox Capsule is mainly used for reducing triglyceride levels in patients who do not respond adequately to other treatments (such as statins or fibrates).
공고 • Feb 24SSY Group Limited Provides Update on Product DevelopmentSSY Group Limited announced that the Group's Piribedil has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Piribedil is mainly used for the treatment of Parkinson's disease and circulatory disturbance.
공고 • Jan 20Ssy Group Limited Obtains Approval for Drug Production and Registration for Composite Potassium Hydrogen Phosphate Injection (5Ml) from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Composite Potassium Hydrogen Phosphate Injection (5ml) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug, regarded as passing the consistency evaluation and the first of such approval for the PRC entities. Composite Potassium Hydrogen Phosphate Injection is a compound preparation which is mainly used for correction of hypophosphatemia in adult and child patients and for parenteral nutrition in adult and child patients when enteral nutrition is impossible, insufficient or prohibited. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Vortioxetine Hydrobromide Tablets (5mg) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Vortioxetine Hydrobromide Tablet is mainly used for the treatment of depression in adults. As stated in the Company's announcement dated 27 December 2023, the Group's Vortioxetine Hydrobromide bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.
공고 • Jan 08SSY Group Limited Obtains Approval for Drug Production and Registration for Vonoprazan Fumarate TabletsThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Vonoprazan Fumarate Tablets (20mg and 10mg) from National Medical Products Administration of China (the ‘NMPA’), being under type 4 chemical drug and regarded as passing the consistency evaluation. Vonoprazan Fumarate Tablet is mainly used for the treatment of reflux esophagitis. As stated in the Company's announcement dated 16 December 2024, the Group's Vonoprazan Fumarate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.
공고 • Jan 06Ssy Group Limited Announces That the Benidipine Hydrochloride Obtained Approval for Registration from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group's Benidipine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Benidipine Hydrochloride is mainly used for the treatment of primary hypertension and angina pectoris.
공고 • Dec 30SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Nikethamide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Nikethamide is a central nervous system stimulant, which is mainly used for the treatment of central respiratory depression and respiratory depression of various causes.
공고 • Dec 27+ 1 more updateSSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Furosemide Injection (2ml: 20mg). Furosemide Injection is mainly used for the treatment of various diseases with edema, hypertension, hyperkalemia and hypercalcemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and acute drug poisoning (such as barbiturate poisoning), and for the prevention of acute kidney failure.
공고 • Dec 16SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announce that the Group's Vonoprazan Fumarate has obtained the approval for registration from the National Medical Products Administration of China (the ‘NMPA’) to become a bulk drug for the preparations on the market. Vonoprazan Fumarate is mainly used for the treatment of reflux esophagitis. In addition, the Board is also announced that the Group's Dronedarone Hydrochloride has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market, being the third of such approvals for the PRC entities. Dronedarone Hydrochloride is an antiarrhythmic drug. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Dec 02SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Compound Sodium Acetate and Glucose Injection (500ml and 200ml) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation, and was among the first three PRC manufacturers with approvals for such drug production. Compound sodium Acetate andGlucose Injection is mainly used in replenishing and maintaining water and electrolytes as well as supplying energy when oral administration is not possible or insufficient, and is the latest generation of sugar-containing sodium acetate balanced crystalloid. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Nov 27SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency EvaluationSSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Glycerol Fructose and Sodium Chloride Injection (250ml). Glycerol Fructose and Sodium Chloride Injection is mainly used for the treatment of acute or chronic intracranial pressure increase and cerebral edema which are caused by cerebrovascular disease, brain trauma, brain tumors, intracranial inflammation, etc.
공고 • Nov 05SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)The board of directors (the "Board") of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Phenylephrine Hydrochloride Injection (1ml:10mg) from National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Phenylephrine Hydrochloride Injection is mainly used in maintaining blood pressure during treatment of shock and during anesthesia, and is also used in controlling paroxysmal supraventricular tachycardia. As stated in the Company's announcement dated 23 July 2024, the Group's Phenylephrine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.
공고 • Oct 21SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of ChinaSSY Group Limited announced that the Group has obtained the approval for drug production and registration for Cycloserine Capsules (0.25g) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. Cycloserine Capsule is mainly used for the treatment of active pulmonary tuberculosis and extrapulmonary tuberculosis which are caused by susceptible tuberculosis bacteria and after ineffective first-line anti-tuberculosis drug treatment. It can also be used for the treatment of acute urinary tract infections caused by susceptible gram-positive bacteria and gram-negative bacteria. The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Lornoxicam for injection (8mg) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Lornoxicam for injection is mainly used for the short-term treatment of adults' acute pain from mild to moderate level which are not suitable for oral drug administration.
공고 • Oct 14SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in ChinaSSY Group Limited announce that the Group's Cisatracurium Besilate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Cisatracurium Besilate is a muscle relaxant which is mainly used for muscle tension, sedation, general anesthesia during tracheal intubation and as an auxiliary medication to general anesthesia. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 18%After last week's 18% share price gain to HK$4.46, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 10x in the Pharmaceuticals industry in Hong Kong. Total returns to shareholders of 31% over the past three years.
Recent Insider Transactions • Sep 25Chairman & CEO recently bought HK$4.8m worth of stockOn the 24th of September, Jiguang Qu bought around 1m shares on-market at roughly HK$3.87 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$21m worth in shares.
공고 • Sep 09SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Nefopam Hydrochloride Injection (2ml: 20mg), being the first of such approval for the PRC entities. Nefopam Hydrochlorides Injection is mainly used for symptomatic treatment of acute pain, especially for postoperative pain.
Recent Insider Transactions • Sep 04Chairman & CEO recently bought HK$1.5m worth of stockOn the 2nd of September, Jiguang Qu bought around 400k shares on-market at roughly HK$3.81 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$16m worth in shares.
공고 • Sep 02SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicorandil Tablets (5mg) from National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. Nicorandil Tablet is mainly used in the treatment of angina. As stated in the Company's announcement dated 9 October 2023, the Group's Nicorandil bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.
Reported Earnings • Aug 31First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)First half 2024 results: EPS: HK$0.23 (up from HK$0.21 in 1H 2023). Revenue: HK$3.34b (flat on 1H 2023). Net income: HK$685.7m (up 7.4% from 1H 2023). Profit margin: 21% (up from 19% in 1H 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Declared Dividend • Aug 30First half dividend increased to HK$0.08Dividend of HK$0.08 is 14% higher than last year. Ex-date: 12th September 2024 Payment date: 27th September 2024 Dividend yield will be 4.7%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (161% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공고 • Aug 28+ 1 more updateSSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024SSY Group Limited Announced the Interim Dividend of HKD 0.08 per share for the six months ended 30 June 2024. Ex-dividend date is on 12 September 2024 with Record date is on 20 September 2024. Payment date is on 27 September 2024.
공고 • Aug 16SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024SSY Group Limited announced that they will report first half, 2024 results on Aug 28, 2024
공고 • Aug 07SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Entacapone, Levodopa and Carbidopa Tablets (II) (Entacapone 200mg, Levodopa 100mg, Carbidopa 25mg) and Fluvoxamine maleate Tablets (100mg) from the National Medical Products Administration of China (the "NMPA"), both being under type 4 chemical drug and regarded as passing the consistency evaluation, with Entacapone, LevODopa and Carbidopa TableTS (II) being the first of such approval for the PRC entities. Entacapone, Levomopa and Carbidopa Tablet (II) are mainly used in adult patients with Parkinson's disease who have end-of-dose motor function fluctuations that cannot be controlled by levodopa/dopa decarboxylase (DDC) inhibitor therapy, and Fluvoxamine maleates Tablets are mainly used in the treatment of depression and obsessive-compulsive disorder. As stated in the Company's announcement dated 27 September 2023, the Group's Entacapone bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. The Board also announced that the Group has obtained the approval for drug production and registration for Lipid Emulsion (10%)/Amino Acids (15) and Glucose (20%) Injection (1000ml and 1500ml) from the NMPA, both being under type 4 chemical Drug, regarded as passing the consistency evaluation and the second of such approvals for the PRC entities. This three-ch chambers-bag injection is mainly used for parenteral nutrition when enteral nutrition is not feasible, insufficient or prohibited.
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to HK$3.69, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 8x in the Pharmaceuticals industry in Hong Kong. Total loss to shareholders of 20% over the past three years.
공고 • Jul 23SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Phenylephrine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Phenylephrine Hydrochloride is mainly used in the treatment of low blood pressure caused by vasodilation during anesthesia.
공고 • Jul 16SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Betahistine Mesilate Tablets (6mg) from National Medical Products Administration of China (the "NMPA"), being the first of such approval for the PRC entities, under type 4 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 27 June 2024, the Group's Betahistine Mesilate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Betahistine Mesilate Tablet is mainly used in the treatment of dizziness and lightheadedness associated with Meniere's disease, Meniere's syndrome and vertigo. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Jun 29SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Deferasirox has obtained the approval for registration from the National Medical Products Administration of China (the "NMPA") to become a bulk drug for the preparations on the market. Deferasirox is mainly used in patients with iron accumulation due to the need for long-term blood transfusions (such as thalassemia or other rare anemias patients). In addition, the Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Esmolol Hydrochloride Injection (10ml:0.1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Esmolol hydrochloride Injection is mainly used in supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Jun 24SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Etomidate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Etomidate is mainly used as an anesthetic drug, and is included in the list of controlled category II psychotropic drugs of China. Currently, the Group has held the psychotropic drugs production licences in China and complied with the relevant regulations on production and management. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Jun 18SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Esmolol Hydrochloride and Sodium Chloride Injection (100ml) from National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Esmolol Hydrochlorides and Sodium Chloride In injection is mainly used in supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Jun 08SSY Group Limited Announces Update on Product DevelopmentSSY Group Limited announced that the group's Butylphthalide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Butylphthalide is mainly used in the treatment of minor or moderate ischemic stroke (also known as brain attack).
공고 • May 31+ 1 more updateSSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of ChinaThe board of directors of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") announced that the Group's Trelagliptin Succinate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the fourth of such approval in the PRC. Trelagliptin Succinate is mainly used for the treatment of type 2 diabetes with its tablets form being a long-acting inhibitor.
공고 • May 29SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration ofChina has approved the addition of 50ml:4.2g specification and passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Sodium Bicarbonate Injection. Sodium Bicarbonate Injection is mainly used in the treatment of metabolic acidosis, alkalinization of urine, treatment of symptoms caused by hyperacidity and treatment of intravenous intoxication by certain drugs.
공고 • May 28Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of ChinaSSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Ondansetron Hydrochloride Injection (4ml:8mg and 2ml:4mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Ondansetron Hydrochloride Injection is mainly used in the control of nausea and vomiting caused by cancer chemotherapy and radiation therapy, and in the prevention and treatment of post-surgery nausea and vomiting.
Upcoming Dividend • May 14Upcoming dividend of HK$0.10 per shareEligible shareholders must have bought the stock before 21 May 2024. Payment date: 04 June 2024. Payout ratio is a comfortable 38% but the company is paying out more than the cash it is generating. Trailing yield: 3.5%. Lower than top quartile of Hong Kong dividend payers (7.5%). In line with average of industry peers (3.3%).
공고 • Apr 03SSY Group Limited Provides Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Cefuroxime Axetil for Suspension (0.25g and 0.125g) from National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation, with 0.25g specification being the first and 0.125g specification being the second of such approvals for the PRC entities. Cefuroxime Axetil for Suspension is mainly used in the treatment of infectious diseases caused by susceptible bacteria. In addition, the Board announced that the Group has obtained the approvals for drug production and registration for Lidocaine Hydrochloride Injection (20ml:0.4g, 10ml:0.2g and 5ml:0.1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 23 January 2024, the Group's Lidocaine Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Lidocaine Hydrochloride Injection is a local anesthesia and antiarrhythmic drug which is mainly used in infiltration anesthesia, epidural anesthesia, surface anesthesia and nerve conduction block.
Recent Insider Transactions • Mar 29Chairman & CEO recently bought HK$2.5m worth of stockOn the 28th of March, Jiguang Qu bought around 500k shares on-market at roughly HK$4.91 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$24m worth in shares.
공고 • Mar 28SSY Group Limited, Annual General Meeting, May 17, 2024SSY Group Limited, Annual General Meeting, May 17, 2024, at 14:00 China Standard Time. Location: Rooms 4902-03, 49th Floor, Central Plaza, 18 Harbour Road Wanchai Hong Kong
Reported Earnings • Mar 28Full year 2023 earnings released: EPS: HK$0.44 (vs HK$0.38 in FY 2022)Full year 2023 results: EPS: HK$0.44 (up from HK$0.38 in FY 2022). Revenue: HK$6.46b (flat on FY 2022). Net income: HK$1.32b (up 17% from FY 2022). Profit margin: 20% (up from 18% in FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
공고 • Mar 27SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024SSY Group Limited announced Final Dividend for the year ended 31 December 2023 of HKD 0.1 per share with Ex-dividend date 21 May 2024; Record date 22 May 2024 & Payment date 04 June 2024.
공고 • Mar 21SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Benserazide hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Berazide hydrochloride is a decarboxylase inhibitor, which is mainly used in combination with Levodopa for the treatment of Parkinson's disease.
공고 • Mar 16SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024SSY Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024
공고 • Mar 02SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Nicorandil for Injection is a type of lyophilized powder for injection. It is the third approved lyophilized powder for injection products of the Group, and is mainly used for the treatment of unstable angina.
공고 • Mar 01SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the MarketThe board of directors of SSY Group Limited announced that the Group's Norepinephrine bitartrate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Norepinephrine bitartrate is an adrenergic receptors agonist, which is mainly used clinically in anti-shock by causing extreme contraction of blood vessels to increase blood pressure and coronary blood flow as well as by strengthening myocardial contraction and increasing cardiac output.
공고 • Feb 28SSY Group Limited Receives Approval for Gliclazide TabletThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of generic Drugs for the Group's Gliclazide Tablets (80mg). Gliclazide Tablet is mainly used in adult patients with type 2 diabetes when dietary control, exercise, and weight loss are not enough to control blood sugar level.
공고 • Feb 24SSY Group Limited Provides Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Sodium Bicarbonate Ringer's Injection (500ml) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. Sodium Bicarbonate Ringer's Injection is mainly used for replenishing extracellular fluid when circulating blood volume and interstitial fluid decrease, and for correction of metabolic acidosis.
공고 • Feb 19SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Propofol Medium and Long Chain Fat Emulsion Injection (20ml: 0.2g and 10ml: 0.1g) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and being the first approved fat emulsion ampoule injection product of the Group. Propofol Medium and Long Chain Fat Emulsion Injection is a short-acting intravenous anesthetic for general anesthesia. It is mainly used for induction and maintenance of general anesthesia, sedation of patients undergoing diagnostic procedures and surgeries, and sedation of patients receiving assisted ventilation treatment.
공고 • Jan 31SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Isoprenaline hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the second of such approval in the PRC.
공고 • Jan 24SSY Group Limited Provides Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group's Lidocaine hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Lidocaine hydro chloride is a local anesthesia and antiarrhythmic drug. It is mainly used in infiltration anesthesia, epidural anesthesia, surface anesthesia and nerve conduction block.
공고 • Jan 19+ 1 more updateSSY Group Limited Appoints Liu Wenjun as Non-Executive DirectorThe board (the "Board") of directors (the "Director(s)") of SSY Group Limited (the "Company") announced that Mr. Liu Wenjun ("Mr. Liu") has been appointed as a non-executive Director of the Company with effect from 19 January 2024. Mr. Liu Wenjun, aged 52, currently serves as the general manager of the Xindu Base of Sichuan Kelun Pharmaceutical Company Limited ("Sichuan Kelun", a substantial shareholder of the Company interested in approximately 20.43% of the issued share capital of the Company), a position he has taken since 2013. He was the general manager of Kunming Nanjiang Pharmaceutical Co. Ltd. from 2005 to 2013. He served as a workshop supervisor of Sichuan Kelun from 2002 to 2005, and a technician at the Sichuan Antibiotics Laboratory of the National Medical Products Administration from 1996 to 2002. Mr. Liu graduated from Chengdu University of Traditional Chinese Medicine with a Bachelor of Science degree and holds the qualification of a Senior Engineer in the People's Republic of China.
공고 • Jan 17Ssy Group Limited Provides Update on Product DevelopmentSSY Group Limited announced that the Group has obtained the approvals for drug production and registration for Magnesium Sulfate Injection (20ml: 10g, 10ml: 5g and 2ml: 1g) and Vortioxetine Hydrobromide Tablets (10mg) from the National Medical Products Administration of China, being under type 3 chemical drug and type 4 chemical drug respectively, and regarded as passing the consistency evaluation. As an anticonvulsant drug, Magnesium Sulfate Injection is a mainly used in pregnancy-induced hyper-tension for the treatment of pre-eclampsia and eclampsia by reducing blood pressure. Vortioxetine Hydrobromide Tablets is mainly used for the treatment of depression in adults.
공고 • Jan 10SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Chlorphenamine Maleate Injection (2ml: 20mg and 1ml: 10mg), in which the 2ml: 20mg specification being the first and 1ml: 10mg specification being the second of respective approvals for the PRC entities. Chlorphenamine Maleate Injection is mainly used in the treatment of allergic rhinitis, and can also be used for colds or sinusitis, mucocutaneous allergy, and control of drug eruption and contact dermatitis.
공고 • Jan 05SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of ChinaThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Ropivacaine Hydrochloride and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approval for the PRC entities. Ropivacaine Hydro chloride and Sodium Chloride injection is mainly used in local or regional anesthesia and acute pain management for surgery. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
공고 • Dec 27SSY Group Limited Provides Update on Product DevelopmentThe board of directors (the "Board") of SSY Group Limited announce that the Group's Vortioxetine hydrobromide has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Vortioxetine hydrobromide is a 5-hydroxytryptamine (5-HT) reuptake inhibitor, and is an agonist, partial agonist or antagonist of certain types of 5-HT receptors. It is mainly used in the treatment of major depressive disorder (MDD) in adults.
Recent Insider Transactions • Dec 06Chairman & CEO recently bought HK$4.7m worth of stockOn the 5th of December, Jiguang Qu bought around 1m shares on-market at roughly HK$4.74 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jiguang has been a buyer over the last 12 months, purchasing a net total of HK$24m worth in shares.
공고 • Dec 01SSY Group Limited Announces Update on Product DevelopmentThe board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Tedizolid Phosphate Tablets (200mg) from the National Medical Products Administration of China (the "NMPA"), being under type 4 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 11 April 2023, the Group's Tedizolid phosphate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Tedizolid Phosphate Tablet is mainly used in the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of Gram-positive bacteria (including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus, and Enterococcus facadeecalis). This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.